Government versus FDA: The RESULT Act

29 February 2016
fda-blog-700

US Senator Ted Cruz wants to change the way the Food and Drug Administration approves drugs. Indeed, the introduction of his “Reciprocity Ensures Streamlined Use of Lifesaving Treatments (RESULT) Act” has sparked hot debate, says Dr Nicola Davies in her monthly FDA Blog for The Pharma Letter.

In this draft legislation, Sen Cruz proposes that Congress should be allowed to overrule the FDA if a potentially life-saving drug is rejected, and also that drugs already approved in certain developed countries, such as Japan, Canada, Australia and Israel, should be approved on a reciprocal basis.

Sen Cruz wants the FDA to be given thirty days to evaluate evidence in favor of a drug approved elsewhere in the world. Should it decide against reciprocal approval, then Congress will have the power to overturn this decision by a majority vote.

What implications will this legislation, if approved, have for the FDA’s ability to ensure that medications are safe and effective?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical